Shekari, Mahnaz
Verwer, Eline E.
Yaqub, Maqsood
Daamen, Marcel
Buckley, Christopher
Frisoni, Giovanni B.
Visser, Pieter Jelle
Farrar, Gill
Barkhof, Frederik
Gispert, Juan Domingo http://orcid.org/0000-0002-6155-0642
Boellaard, Ronald
,
Funding for this research was provided by:
Innovative Medicines Initiative 2 Joint Undertaking (115952)
Article History
Received: 20 April 2023
Accepted: 12 October 2023
First Online: 31 October 2023
Declarations
:
: Not applicable.
: Not applicable.
: CB is an employee of GE Healthcare. GBF reports grants from Avid Radiopharmaceuticals, Biogen, GE International, Guerbert, IXICO, Merz Pharma, Nestlé, Novartis, Eisai, Piramal, Roche, Siemens, Teva Pharmaceutical Industries, and Vifor Pharma; he has received personal fees from AstraZeneca, Avid Radiopharmaceuticals, Biogen, Roche, Diadem, Neurodiem, Elan Pharmaceuticals, GE International, Lundbeck, Pfizer, and TauRx Therapeutics. PV has served as a member of the advisory board of Roche Diagnostics and received non-financial support from GE Healthcare, research support from Biogen, and grants from Bristol-Myers Squibb, EU/EFPIA Innovative Medicines Initiative Joint Undertaking, EU Joint Programme–Neurodegenerative Disease Research (JPND and ZonMw). GF is an employee of GE Healthcare. FB Steering committee or iDMC member for Biogen, Merck, Roche, EISAI, and Prothena. Consultant for Roche, Biogen, Merck, IXICO, Jansen, and Combinostics. Research agreements with Merck, Biogen, GE Healthcare, and Roche. Co-founder and shareholder of Queen Square Analytics LTD. JG has received research support from GE Healthcare, Roche Diagnostics, F. Hoffmann—La Roche, and speaker's fees from Biogen and Philips. In addition, he holds a “Ramón y Cajal” fellowship (RYC-2013-13054), has received research support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking AMYPAD grant agreement no 115952, and from Ministerio de Ciencia y Universidades (grant agreement RTI2018-102261). RB is a scientific advisor for EARL (unpaid). The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.